A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Part 1: An open label, dose and age escalation phase to evaluate the safety and
immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults
aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with
an mRNA (messenger ribonucleic acid) vaccine for the prevention of COVID-19.
Part 2: This phase will assess the efficacy of prophylactic VXA-CoV2-1.1-S against confirmed
COVID-19 occurring from 7 days after second dose with a repeat-dose vaccination schedule in
healthy adults compared to placebo. Safety and immunogenicity of VXA-CoV2-1.1-S will also be
evaluated in this phase.